Psychotic Disorders Clinical Trial
— FFTOfficial title:
Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders
Verified date | March 2020 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present study aims to :
1. compare different approaches (high intensity vs. low intensity) to training community
providers (those who routinely treat young patients with bipolar disorder, psychosis, or
sub-threshold high-risk conditions) on the implementation of family-focused treatment
(FFT);
2. assess the cost of FFT training and implementation support; and
3. determine whether these different forms of clinician training are associated with
different outcomes over 1 year among patients with early-onset mood and psychotic
disorders.
Status | Completed |
Enrollment | 133 |
Est. completion date | January 1, 2019 |
Est. primary completion date | January 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years to 25 Years |
Eligibility |
Inclusion Criteria: For patient participants: Youth (13-17 years of age) and young adults (18-25 years of age) with the following: 1. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnosis of bipolar disorder (BD) type I or II; 2. DSM-5 diagnosis of schizophrenia, schizophreniform disorder, or psychosis not otherwise specified [NOS]; 3. DSM-5 diagnosis of bipolar disorder, not elsewhere classified (formerly bipolar NOS; see criteria below); or 4. Research classification of ultra high-risk for psychosis. 5. at least one parent or step-parent with whom the subject lives is willing to participate in family treatment sessions; 6. the potential patient and relative(s) participants are able and willing to give written informed assent/consent to participate in the study. Inclusion criteria for family clinicians: 1. works at one of the participating agencies (Harbor/UCLA, San Fernando Mental Health Center, Didi Hirsch Mental Health Services) 2. provides mental health care for youth or young adults with (or at risk for) bipolar or psychotic disorders 3. are licensed (medical, psychologist, clinical social work, marriage and family therapy) mental health provider or are eligible to be a licensed mental health provider (social work / psychology intern or extern, psychiatry resident, psychiatry child and adolescent psychiatry fellow) in the State of California working under the direct supervision of a licensed mental health professional. Exclusion Criteria for patients: 1. a DSM-5 diagnosis of autism or pervasive developmental disorder, by history or medical records; 2. evidence of mental retardation by history or medical records (IQ < 70); 3. diagnosable and active substance or alcohol abuse or dependence disorders in the 4 months prior to study recruitment, although a lifetime history of substance or alcohol disorders can be present if the patient has been abstinent for at least 4 months; 4. a life-threatening medical disorder that requires immediate hospitalization or other emergency treatment; 5. evidence of current sexual or physical abuse of the child, and/or current domestic abuse between the adult partners. These situations usually require notification of the Department of Child Services and forms of treatment other than family therapy. Exclusion criteria for clinicians: none. |
Country | Name | City | State |
---|---|---|---|
United States | Didi Hirsch Mental Health Services | Culver City | California |
United States | San Fernando Mental Health Center | Granada Hills | California |
United States | Harbor/UCLA Outpatient Psychiatry Porgram | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles |
United States,
Miklowitz DJ, Schneck CD, Singh MK, Taylor DO, George EL, Cosgrove VE, Howe ME, Dickinson LM, Garber J, Chang KD. Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy. J Am Acad Child Adolesc Psychiatry. 2013 Feb;52(2):121-31. doi: 10.1016/j.jaac.2012.10.007. Epub 2013 Jan 2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Therapist Competency and Adherence Rating | This is a measure of how well the clinician administered family-focused treatment (FFT) based on ratings of audiotapes of family intervention sessions. These ratings are made every third session in both training conditions. This is an overall rating that can vary from 1 (nonadherent) to 7 (excellent adherence) | One year | |
Secondary | Patient Health Questionnaire, 9 | Self-rating of depression and impairment, administered at baseline, 4 months, and 12 months | 1 year | |
Secondary | Young Mania Rating Scale | Mania symptoms (based on observer report) at baseline, 4 months and 12 months | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00130676 -
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
|
Phase 3 |